What REPO4EU does

REPO4EU is an EU-funded Research and Innovation Action (RIA) under the Horizon Europe programme (Grant Agreement No. 101057619), established in 2022 and coordinated by Prof. Harald Schmidt at Maastricht University. The project brings together 28 partners across 10 countries (Netherlands, Germany, Austria, Spain, Sweden, Romania, Belgium, Portugal, Switzerland, and the United States) with a total budget of approximately €23-25M disbursed over 84 months. Its stated objective is to build the first Euro-Global digital infrastructure specifically designed for mechanism-based drug repurposing, addressing the fragmentation of repurposing workflows, the absence of structured decision-support for ethics, regulation, IP, and reimbursement, and the "valley of death" between academic discovery and patient access. The legal entity responsible for communications is AUSTRALO INTERINNOV MARKETING LAB SL, a private company established in Spain, while project coordination sits with Maastricht University.

The platform is modular and FAIR-data-driven, integrating a bioinformatics toolkit (Drugst.One for in-silico candidate identification that narrows drug options to 2-3 per query; DrugRepoChatter AI chatbot grounded in 285 expert-curated open-access articles; DrugRepoChatter-retrieval plus a REPO AI Assistant planned to upgrade to Agentic AI in the 2026 beta), curated scientific databases built on a NeDRex-based knowledge graph (drug-target, side-effect, and disease-association data), decision-support tools (SMART for health technology assessment; REPOscope for patent and freedom-to-operate analysis), and a Registry of Academic Trial Sites for Phase I/II investigator-initiated trials. Adjacent ecosystem assets include the Drug Repurposing Central publishing portal co-developed with ScienceOpen, the Drug Repurposing Journal, the DrugRxiv preprint server, the annual RExPO conference series (five editions across Maastricht, Stockholm, Munich, Barcelona, and Berlin), and the Special Interest Group on Drug Repurposing (SIG-DR) for policy advocacy.

REPO4EU is grant-funded rather than commercially monetized. The Horizon Europe grant (supplemented by Swiss SERI co-funding) is the primary revenue source; ancillary inflows come from tiered RExPO conference registrations (€50-€490 per ticket) and an emerging freemium-style platform access model that is not yet revenue-generating. Customer and stakeholder segments are institutional: academic researchers and clinicians, biotech SMEs, pharmaceutical industry partners, patient advocacy organizations (e.g., EURORDIS, Duchenne Parent Project), and EU regulatory/HTA bodies (e.g., AEMPS, CBG MEB, NOMA). A post-grant sustainability model is not clearly articulated, and the project timeline (~2029) introduces terminal-value risk that any commercial spinout or follow-on funding would need to address.

Name

REPO4EU

Legal name

AUSTRALO INTERINNOV MARKETING LAB SL

Website

https://repo4.eu

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

11–50 employees

Short description

REPO4EU is an EU-funded Horizon Europe research consortium of 28 partners building a global digital platform for mechanism-based drug repurposing, serving academic researchers, clinicians, biotech industry, regulators, and patient organizations across 10 countries.

Ownership category

akta.pro rank

Product category

Drug Repurposing Software

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Custom Computer Programming Services (541511)

SIC

Services-Prepackaged Software (7372)

akta.pro primary industry

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

akta.pro secondary industries

Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI), Translational Medicine & Biomarkers (HLAIALAF), Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity) (HLAGAAAD)

Keywords

• Drug repurposing platform
• Bioinformatics software
• Biomedical knowledge graph
• Clinical trial registry
• Scientific publishing tools

Headquarters

HQ city

Maastricht

HQ country

Netherlands

HQ region

Europe

Offices4 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. EU Research Grant (Horizon Europe): REPO4EU is a EU-funded Research and Innovation Action (RIA) supported by Horizon Europe Programme under Grant Agreement No. 101057619. The project runs for 84 months (7 years) and is co-funded by the Swiss State Secretariat for Education, Research, and Innovation (SERI). This is the primary funding source for all consortium activities including platform development, clinical trials, and dissemination.
2. Conference Registration Fees: The annual RExPO conference series generates revenue through tiered registration fees. Pricing ranges from €100 (patients & patient organisations) to €490 (full 2-day general admission), with discounts for startups (€310-€350), academia (€260-€300), and PhD students (€160-€190). Group discounts of 10% apply for 3+ tickets purchased together.
3. Platform Access & Matchmaking Services: The platform provides bioinformatics support, matchmaking services, and curated resources for drug repurposing projects. While primarily grant-funded, the platform aims to create sustainable infrastructure for the global drug repurposing community.

Pricing tiers

Go-to-market motion1 record

Distribution channels5 records

Marketing channels9 records

Core offering

REPO4EU operates a Euro-Global digital platform for mechanism-based drug repurposing, integrating bioinformatics tools (Drugst.One, DrugRepoChatter), curated scientific databases, a NeDRex-based knowledge graph, AI assistants, decision-support guides (SMART for health economics, REPOscope for patents), and an integrated matchmaking system into one FAIR-data-driven workspace. The platform supports researchers across the full translational chain from target identification and preclinical validation through clinical trials, regulatory guidance, IP strategy, and reimbursement planning.

Product overview

REPO4EU is a Euro-Global Platform for Mechanism-based Drug Repurposing built as a modular digital ecosystem. At its core is the REPO4EU Platform — a unified online workspace integrating bioinformatics tools (Drugst.One, DrugRepoChatter), curated scientific databases, the REPO4EU Knowledge Base (a unified knowledge graph of drug-target interactions, diseases, and gene associations), decision-support guides (SMART for health economics, REPOscope for patents), an REPO AI Assistant, and an integrated matchmaking system. The platform also includes the Registry of Academic Trial Sites for Phase I/II clinical trials. Adjacent to the platform, REPO4EU operates Drug Repurposing Central, a joint publishing portal with ScienceOpen encompassing the Drug Repurposing journal, DrugRxiv preprint server, and conference proceedings. The ecosystem is anchored by the annual RExPO conference series and complemented by the Special Interest Group – Drug Repurposing (SIG-DR) for policy and reimbursement advocacy. The platform is in alpha release with a beta version planned for autumn 2026.

Differentiator

Problem solved

Functional benefit

Brands

• RExPO Conference Series: International Conference Series on Systems Medicine, AI & Drug Repurposing. RExPO22 (Maastricht 2022), RExPO23 (Stockholm 2023), RExPO24 (Munich 2024), RExPO25 (Barcelona 2025), RExPO26 (Berlin 2026).
• Drug Repurposing Central
• DrugRxiv
• Drug Repurposing Journal
• DrugRepoChatter
• SMART

Products and services

• REPO4EU Platform A modular digital platform that integrates bioinformatics tools, curated scientific databases, decision-support guides, an AI Assistant, and a matchmaking system into a unified workspace guiding researchers from idea to patient impact across the full drug repurposing value chain.
• Drugst.One A bioinformatics tool within the REPO4EU Platform that performs in-silico analysis to identify drug repurposing candidates with extreme precision, narrowing candidate lists to a small subset of highly relevant options. Designed for biomedical scientists without bioinformatics coding expertise.
• DrugRepoChatter An AI-powered chatbot that helps drug repurposing researchers navigate relevant scientific literature by answering natural language queries against a curated database of 285 open-access expert-selected articles, covering computational tools, databases, and methods.
• SMART Tool Structured Modelling Approach for Appropriate Reporting and Trade-offs (SMART) is a step-by-step decision-analytic tool for health technology assessment that guides researchers through making, reporting, and justifying simplified modelling choices in data-limited contexts.
• REPOscope A prior-art knowledge base tailored to drug repurposing patents, available within the REPO4EU Platform to help researchers navigate intellectual property landscapes and freedom-to-operate analysis.
• REPO AI Assistant An intelligent AI-powered assistant within the REPO4EU Platform that guides users through drug repurposing workflows by finding the right tools, resources, and data based on natural language queries. The beta version will use Agentic AI architectures.
• REPO4EU Knowledge Base A unified knowledge graph built by integrating drug-target interactions, side effects, disease associations, and gene regulation data from multiple databases into a single accessible resource for researchers.
• Registry of Academic Trial Sites A registry of Phase I/II clinical trial sites within the REPO4EU Platform that helps researchers locate clinical trial test sites for early-phase trials, supporting investigator-initiated trials.
• Drug Repurposing Central A premier open-access publishing portal created as a joint enterprise by REPO4EU and ScienceOpen, providing comprehensive resources for drug repurposing research including the Drug Repurposing journal, DrugRxiv preprint server, conference proceedings, and computational tools databases.
• Drug Repurposing Journal An open-access, interdisciplinary peer-reviewed journal covering basic science, translational, and clinical research in drug repurposing. Published under CC BY 4.0 license via ScienceOpen.
• DrugRxiv A pioneering preprint server specifically designed for the drug repurposing community, enabling researchers to share early-stage results rapidly with automated SciScore evaluation and Crossref similarity checks.
• Network and Systems Medicine Journal An open-access peer-reviewed journal focused on interdisciplinary approaches applying network science and systems thinking to medicine, covering network medicine, mechanism-based disease definitions, multiscale modeling, virtual patient repositories, and precision medicine.
• RExPO Conference Series An annual international conference series on Systems Medicine, AI and Drug Repurposing organized by REPO4EU, bringing together clinicians, researchers, industry, SMEs, patient organizations, regulators, payers, and policymakers across European cities.

Quantifiable outcome

• Drug candidates narrowed to 2-3 precision options per query (vs. hundreds in traditional approaches)
• +3 more outcomes

Named customers11 records

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability9 records

Feature8 records

Partnerships

27 partnerships are on record, tiered platinum sponsor, key, supporting and core.

• Buchanan's Life Sciences Industry Groupplatinum sponsorGTM or Marketing Partner · 1 September 2026Platinum sponsor for RExPO26. Offers FDA regulatory, intellectual property, litigation, and government relations services. Supports clients across the full product lifecycle from conception to commercialization.
• EURORDIS — European Organisation for Rare DiseaseskeyStrategic or Co-development Partner · 1 January 2025François Houÿez represents EURORDIS in SIG-DR Policy Events and Panel 4 discussions on reimbursement innovation. EURORDIS advocates for fair returns on investment for repurposed drugs and equitable patient access across Europe.
• Duchenne Parent Project (Netherlands)keyStrategic or Co-development Partner · 1 January 2025Anneliene H. Jonker participates in SIG-DR Policy Events, representing patient organizations in Panel 1 on patients' perspectives. Contributing to advocacy for faster access to repurposed therapies for rare diseases.
• AEMPS — Agencia Española de Medicamentos y Productos Sanitarios (Spain)keyStrategic or Co-development Partner · 1 January 2025Yoana Nuevo Ordóñez contributes to Panel 2 on regulatory innovations facilitating drug repurposing. Represents the Spanish medicines agency in SIG-DR policy discussions on regulatory harmonization.
• CBG MEB — Medicines Evaluation Board (Netherlands)keyStrategic or Co-development Partner · 1 January 2025Marjon Pasmooij participates in SIG-DR regulatory panel discussions, representing the Dutch medicines evaluation board in efforts to streamline regulatory pathways for repurposed drugs.
• NOMA — Norwegian Medical Products AgencykeyStrategic or Co-development Partner · 1 January 2025Anja Schiel represents NOMA in regulatory innovation discussions. Active in both RExPO26 speaker lineup and SIG-DR policy events, contributing to regulatory harmonization efforts across Europe.
• Harvard Medical School (USA)keyStrategic or Co-development Partner · 1 January 2025Prof. Aaron S. Kesselheim participates in Panel 2 on regulatory innovations facilitating drug repurposing. Contributes expertise in pharmaceutical law, regulation, and healthcare policy.
• Fast Centre for Future Affordable and Sustainable Therapy Development (FAST, Netherlands)supportingStrategic or Co-development Partner · 1 January 2025Saco de Visser represents FAST in Panel 3 on successes and roadblocks in bringing drug repurposing to patients, contributing to discussions on sustainable therapy development models.
• RePo-SUDOEsupportingStrategic or Co-development Partner · 1 January 2025Hugo A. L. Filipe contributes to Panel 3 discussions and represents the RePo-SUDOE initiative in SIG-DR activities, collaborating on cross-border drug repurposing strategies in the SUDOE region.
• Arega Medical (Netherlands)supportingStrategic or Co-development Partner · 1 January 2025Teun Grooters contributes to Panel 3 on bringing drug repurposing to patients, representing a medical technology company engaged in sustainable therapeutic development.
• H.M. Pharma Consultancy (Austria)supportingStrategic or Co-development Partner · 1 January 2025Hermann Mucke contributes to Panel 3 discussions and is a founding figure in the drug repurposing community, contributing to DrugRepoChatter curation and the Drug Repurposing journal editorial board.
• Amsterdam UMC / RARE-NL (Netherlands)supportingStrategic or Co-development Partner · 1 January 2025Sibren van den Berg participates in Panel 4 on reimbursement innovation for repurposed drugs, representing the Dutch rare disease network in policy discussions.
• Association Internationale de la Mutualité (AIM, Belgium)supportingStrategic or Co-development Partner · 1 January 2025Sibylle Reichert represents AIM in Panel 4 on reimbursement innovation, contributing the perspective of mutual health insurance organizations across Europe.
• Maastricht University Medical Center+ (Maastricht UMC+)coreStrategic or Co-development Partner · 1 January 2025Sabine Grimm from Maastricht UMC+ contributes to Panel 4 on reimbursement innovation. KEMTA (Clinical Epidemiology & Medical Technology Assessment) at Maastricht UMC+ led the development of the SMART tool and supports HTA framework development.
• Maastricht University (Coordinator)coreStrategic or Co-development Partner · 1 September 2022Prof. Harald Schmidt (Professor Emeritus) serves as REPO4EU Coordinator. Maastricht University leads project coordination, clinical validation research, and pharmacology expertise. The university also leads HTA framework development (KEMTA/Maastricht UMC+) and health economics tools including the SMART model.
• Egnosis (Romania)coreStrategic or Co-development Partner · 1 September 2022Romanian IT company leading the technological development of the REPO4EU platform — responsible for overall design, technical development, UX/UI design, backend architecture, and iterative rollout of the platform.
• ScienceOpencoreStrategic or Co-development Partner · 1 September 2022ScienceOpen co-developed Drug Repurposing Central publishing portal with REPO4EU. Hosts DrugRxiv preprint server, Drug Repurposing journal, conference proceedings, and hosts the abstract submission system for RExPO conferences.
• Technical University of Munich (TUM) — DaiSyBio GroupcoreStrategic or Co-development Partner · 1 September 2022TUM's DaiSyBio group, led by Prof. Markus List, builds the REPO4EU knowledge base and knowledge graph for drug repurposing. Contributed to DrugRepoChatter curation (285 articles) alongside 6 institutions.
• University of Hamburg — Institute for Computational Systems Biology (CoSyBio)coreStrategic or Co-development Partner · 1 September 2022Led by Dr. Fernando Delgado-Chávez, this group spearheaded the development of DrugRepoChatter and focuses on generative AI applications for biomedical research and the REPO4EU platform. Key contributor to Work Package 2 on AI and bioinformatics.
• STALICLA DDS (Spain)coreStrategic or Co-development Partner · 1 September 2022Biopharmaceutical company contributing bioinformatics expertise, precision medicine development, and tool curation to DrugRepoChatter. Led by Emre Guney, a recognized expert in network medicine and drug repurposing.
• University Hospital Essen (Germany)coreStrategic or Co-development Partner · 1 September 2022Dr. Ana Casas leads a research group focused on network pharmacology for neurovascular diseases and preclinical validation within REPO4EU. She serves as work package leader for preclinical validation activities.
• Ludwig Boltzmann Institute for Network Medicine, University of ViennacoreStrategic or Co-development Partner · 1 September 2022Postdoctoral researcher Cristian Nogales investigates diagnostic and drug repurposing opportunities in cardiovascular-metabolic diseases and low complexity cancers, contributing systems biology and bioinformatics expertise.
• University of Porto (Portugal)coreStrategic or Co-development Partner · 1 September 2022Ana Sofia Carvalho and Filipa Lopes contribute from University of Porto. Filipa Lopes conducts bioethics PhD research within REPO4EU's Ethics team, developing ethics-by-design frameworks and consent documents.
• Brigham and Women's Hospital / Harvard Medical School (USA)coreStrategic or Co-development Partner · 1 September 2022Prof. Joseph Loscalzo (founding figure of Network Medicine) serves as keynote speaker and advisor. Adam Raymakers contributes health economic decision modelling. Harvard contributes to SMART tool development and NeDRex-based platform components.
• Radboud UMC (Netherlands)coreStrategic or Co-development Partner · 1 September 2022Dr. Romana Netea-Maier contributes to clinical and translational research. Mirre Scholte contributes to SMART tool development. Part of the Dutch academic network supporting REPO4EU's HTA and health economics work.
• Concentris Research Management (Germany)coreImplementation/ SI/ Consulting Partner · 1 September 2022Contributed to DrugRepoChatter curation process as part of the 13-member expert annotation team from 6 institutions across the REPO4EU consortium.
• GeneSurge (Germany)coreStrategic or Co-development Partner · 1 September 2022Robert Löwe contributed to DrugRepoChatter curation and bioinformatics tool annotation as part of the expert team supporting REPO4EU's AI and computational drug repurposing work.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Healx: AI-focused drug repurposing company specializing in rare diseases, combining machine learning with biomedical data to accelerate therapy discovery. Closely comparable business model and target disease areas (rare diseases, repurposing).
• Biovista: Drug repurposing company using systematic literature analysis and AI to identify new indications for existing drugs. Comparable focus on mechanism-based repurposing and decision-support tools for pharma.
• BenevolentAI: AI-driven drug discovery and repurposing company using knowledge graphs and machine learning to identify new therapeutic uses for existing drugs. Directly comparable technology approach (network medicine + AI) and similar target user base of pharma/biotech partners.
• Lantern Pharma: AI-driven oncology drug development company with a focus on drug repurposing and combination therapies, using machine learning and genomic data to identify responders. Comparable AI-platform-meets-drug-repurposing model.

Broad incumbents

• Insilico Medicine: AI-driven drug discovery company with end-to-end platform covering target identification through clinical development. Comparable in applying AI to drug repurposing but operates as a fully integrated, venture-backed pharma company.
• Recursion Pharmaceuticals: Large-scale AI drug discovery platform combining high-throughput biology with machine learning. Comparable AI-for-drug-discovery approach but at far greater scale (NASDAQ-listed, hundreds of millions raised) and broader therapeutic scope beyond repurposing.
• Exscientia: AI-driven precision medicine company applying machine learning to small-molecule drug design and repurposing. Comparable in combining AI with pharma partnerships, though Exscientia is publicly listed and operates at greater commercial scale.

Others

• Open Targets: Public-private partnership (GSK, EMBL-EBI, Wellcome Sanger) that builds open-source informatics platforms for systematic target identification and drug discovery. Comparable as a non-profit/open-science platform with academic and pharma partnerships, though focused on target identification rather than full repurposing workflows.

Emerging players

• SEngine Precision Medicine: Precision medicine company using functional genomics and AI to match cancer patients with repurposed drugs. Comparable focus on drug repurposing for precision oncology but with narrower therapeutic focus.
• Pharos AI: AI-driven drug repurposing platform focused on identifying new indications for existing compounds. Comparable technology approach (AI + knowledge graph + repurposing) though smaller and earlier stage.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@repo4eu
• Xx.com/REPO4EU

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about REPO4EU